222 related articles for article (PubMed ID: 23308044)
1. Expression of CCL19 from oncolytic vaccinia enhances immunotherapeutic potential while maintaining oncolytic activity.
Li J; O'Malley M; Sampath P; Kalinski P; Bartlett DL; Thorne SH
Neoplasia; 2012 Dec; 14(12):1115-21. PubMed ID: 23308044
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
[No Abstract] [Full Text] [Related]
3. Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer.
Li J; O'Malley M; Urban J; Sampath P; Guo ZS; Kalinski P; Thorne SH; Bartlett DL
Mol Ther; 2011 Apr; 19(4):650-7. PubMed ID: 21266959
[TBL] [Abstract][Full Text] [Related]
4. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy.
Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576
[TBL] [Abstract][Full Text] [Related]
5. Fusogenic oncolytic vaccinia virus enhances systemic antitumor immune response by modulating the tumor microenvironment.
Nakatake M; Kuwano N; Kaitsurumaru E; Kurosaki H; Nakamura T
Mol Ther; 2021 May; 29(5):1782-1793. PubMed ID: 33348052
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
Deng L; Fan J; Guo M; Huang B
Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
[TBL] [Abstract][Full Text] [Related]
7. Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects.
Sampath P; Li J; Hou W; Chen H; Bartlett DL; Thorne SH
Mol Ther; 2013 Mar; 21(3):620-8. PubMed ID: 23229093
[TBL] [Abstract][Full Text] [Related]
8. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.
Kirn DH; Wang Y; Le Boeuf F; Bell J; Thorne SH
PLoS Med; 2007 Dec; 4(12):e353. PubMed ID: 18162040
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9.
Deng L; Fan J; Ding Y; Zhang J; Zhou B; Zhang Y; Huang B
Oncotarget; 2017 Jun; 8(25):40533-40543. PubMed ID: 28465492
[TBL] [Abstract][Full Text] [Related]
10. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
[TBL] [Abstract][Full Text] [Related]
11. Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review.
Li M; Zhang M; Ye Q; Liu Y; Qian W
Cancer Biol Med; 2023 Aug; 20(9):646-61. PubMed ID: 37615308
[TBL] [Abstract][Full Text] [Related]
12. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
[TBL] [Abstract][Full Text] [Related]
13. Intrapleural interleukin-2-expressing oncolytic virotherapy enhances acute antitumor effects and T-cell receptor diversity in malignant pleural disease.
Ekeke CN; Russell KL; Murthy P; Guo ZS; Soloff AC; Weber D; Pan W; Lotze MT; Dhupar R
J Thorac Cardiovasc Surg; 2022 Apr; 163(4):e313-e328. PubMed ID: 33485667
[TBL] [Abstract][Full Text] [Related]
14. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
Rojas JJ; Sampath P; Hou W; Thorne SH
Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
[TBL] [Abstract][Full Text] [Related]
15. Combination of viral oncolysis and tumor-specific immunity to control established tumors.
Chuang CM; Monie A; Wu A; Pai SI; Hung CF
Clin Cancer Res; 2009 Jul; 15(14):4581-8. PubMed ID: 19584165
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo infection of live tissue with oncolytic viruses.
Diallo JS; Roy D; Abdelbary H; De Silva N; Bell JC
J Vis Exp; 2011 Jun; (52):. PubMed ID: 21730946
[TBL] [Abstract][Full Text] [Related]
17. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.
Galivo F; Diaz RM; Thanarajasingam U; Jevremovic D; Wongthida P; Thompson J; Kottke T; Barber GN; Melcher A; Vile RG
Hum Gene Ther; 2010 Apr; 21(4):439-50. PubMed ID: 19922169
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapeutic potential of oncolytic vaccinia virus.
Thorne SH
Immunol Res; 2011 Aug; 50(2-3):286-93. PubMed ID: 21717084
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models.
Guse K; Sloniecka M; Diaconu I; Ottolino-Perry K; Tang N; Ng C; Le Boeuf F; Bell JC; McCart JA; Ristimäki A; Pesonen S; Cerullo V; Hemminki A
J Virol; 2010 Jan; 84(2):856-66. PubMed ID: 19906926
[TBL] [Abstract][Full Text] [Related]
20. An oncolytic vaccinia virus encoding hyaluronidase reshapes the extracellular matrix to enhance cancer chemotherapy and immunotherapy.
Wang S; Li Y; Xu C; Dong J; Wei J
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]